Fritextsökning
Artiklar per år
Innehållstyper
-
Marie Gårdmark: New incentives for orphan products on its way
"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave for drug development in a broader context", writes Marie Gårdmark in a column.
-
A growing industry in Denmark: “One new life science company a week”
The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage of labour, a new report reveals.
-
Hello Angelica Loskog!
Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.
-
New rules for diagnostic products, but who will certify them? “An extreme shortage area”
In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and Covid-19. However, not one single institute in the entire Nordic region is able to certify the diagnostics companies’ products according to the new regulations. “In the end, it risks affecting patients,” says Anna Lefèvre Skjöldebrand, CEO of Swedish Medtech.
-
Tougher competition as the Novo Nordisk Foundation broadens its programme
Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, which has recently broadened its programme for leading innovators in medical research to apply to the entire Nordic region.
-
When carelessness, forgetfulness and coincidence become the researcher’s best friend
Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advances have come about thanks to completely random incidents and the open-mindedness of scientists who were ready to think outside the box.
-
Lucy Robertshaw: Are we in the perfect storm?
“Is there a perfect storm on the horizon again as elective surgeries were cancelled due to patients being admitted with Covid-19? We now have a long backlog of people who are presenting with chronic diseases that need to access healthcare again”, writes Lucy Robertshaw in a column.
-
This is how Anette Steenberg will put Medicon Valley on the world map
Anette Steenberg has been CEO of the Swedish-Danish life science cluster Medicon Valley Alliance since 1 November last year. Life Science Sweden called her to ask about her visions and the challenges of merging the worlds of Swedish and Danish life science.
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, about 90 patients in Sweden have now been treated with this method. “Almost half of them have
-
Björn Arvidsson: ”We need to change perspective”
If you say “life science” to a person on the street and ask them to explain what it is, you will probably get no good answer. The same question to your network will generate as many versions as the people you ask. Most likely, we will miss many
-
A new international stem cell research centre has been created in Copenhagen
A new centre for stem cell research opened to the public in January. The Novo Nordisk Foundation backs the initiative with the ambition that the centre will advance new medical technology and new stem cell therapies.
-
Life Science Sweden´s international issue is on its way
A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.
-
The route to vaccines for everyone: “We did not just sit around and wait”
The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a proposal, and Richard Bergström did not hesitate. “I already had a notion that this would work,” he says in an interview with Life Science Sweden.
-
Anna Törner: Success requires bold decisions!
“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.
-
Giulia Gaudenzi: Innovation for good
"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively – we need to engage bravely with the politics of poverty and scarcity. Even in life sciences", writes Giulia Gaudenzi in a column.
-
Theranos-skandalen – så gick det till när Elizabeth Holmes lurade USA:s toppinvesterare
Biotechbolaget Theranos var ett av de mest hyllade amerikanska företagen och dess vd Elizabeth Holmes blev en av USA:s yngsta miljardärer. Men 2015 vände allt för den framgångsrika entreprenören och sedan gick det bara utför. I början av den här månaden dömdes hon för bedrägeri av en domstol i Kalifornien.
-
The Oresund region aims at becoming Europe’s microbiome Mecca
The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.
-
Sweden and Denmark – this is how they choose their strategies
Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.
-
Anna Törner: You won’t find this many Concorde projects anywhere else
"Suddenly Concorde projects seem reasonable in life science because it´s about life and death", writes Anna Törner in a column.
-
Urwitz nya investeringsbolag ska miljardsatsa på medtech
Det nybildade investeringsbolaget Segulah Medical Acceleration, SMA, har tagit in 1,2 miljarder kronor med ambitionen att satsa på unga, innovativa bolag inom medtech.
-
Astra Zenecas vaccinresultat ifrågasätts i USA
Astra Zeneca berättade på måndagen om goda resultat för företagets covid-19-vaccin i en fas III-studie. Men nu ifrågasätter amerikanska myndigheter om bilden av studien verkligen är korrekt.
-
ATMP-expert till Eliceras styrelse
Karin Hoogendoorn har valts in i styrelsen för Elicera Therapeutics.
-
Column: Why there cannot be a complete cure for cancer – but there is certainly another way!
"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.
BREAKING